Investigating DNA damage response in advanced endometrial cancer
Pathology Core
['FUNDING_P01'] · DANA-FARBER CANCER INST · NIH-11070326
This study is looking at how advanced endometrial cancer reacts to certain types of damage at the DNA level, and it aims to find helpful markers in tissue samples that could lead to new treatments tailored for patients like you.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11070326 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how advanced endometrial cancer responds to DNA damage and replication stress. Led by experts in pathology and biomarker development, the project aims to analyze human and mouse tissue samples to identify key biomarkers associated with treatment responses. Patients may benefit from innovative therapies targeting specific genetic mutations and pathways involved in their cancer. The research will also explore the potential of enhancing anti-tumor immunity through novel treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with advanced endometrial cancer, particularly those with specific genetic mutations such as TP53.
Not a fit: Patients with early-stage endometrial cancer or those without the targeted genetic mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for women with advanced endometrial cancer.
How similar studies have performed: Previous research has shown promise in targeting DNA damage responses in cancer, indicating potential for success with similar approaches in this study.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SHAPIRO, GEOFFREY I — DANA-FARBER CANCER INST
- Study coordinator: SHAPIRO, GEOFFREY I
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.